Skip to main content
Fig. 2 | BMC Nephrology

Fig. 2

From: Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States

Fig. 2

Proportion of stage 3–5 non-dialysis-dependent chronic kidney disease patients with anemia treated with erythropoietin-stimulating agents, intravenous iron and/or red blood cell transfusion. Panel (a), Medicare-covered patients aged 66–85 years; panel (b), Commercially insured patients aged 18–63 years. ESA, erythropoietin-stimulating agents; IV, intravenous

Back to article page